Source:http://linkedlifedata.com/resource/pubmed/id/12750699
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-5-16
|
| pubmed:abstractText |
Allogeneic peripheral blood stem cell transplantation (PBSCT) has emerged as an alternative to bone marrow transplantation. PBSCT can be associated with a higher incidence of chronic graft-versus-host disease (cGVHD). In this study, we investigated whether there was a correlation between the composition of PBSC grafts (CD34+ and CD3+ cells) and hematological recovery, GVHD, relapse, and relapse-free survival (RFS) after myeloablative HLA-identical sibling PBSCT. The evolution of 100 acute or chronic leukemia patients was analyzed. Neither hematological recovery, acute or cGVHD, nor relapse, was significantly associated with CD3+ cell dose. Increasing CD34+ stem cells was associated with faster neutrophil (P=0.03) and platelet (P=0.007) recovery. Moreover, 47 of the 78 patients evaluable for cGVHD (60%; 95% CI, 49-71%) developed extensive cGVHD. The probability of extensive cGVHD at 4 years was 34% (95% CI, 21-47%) in patients receiving a 'low' CD34+ cell dose (<8.3 x 10(6)/kg), as compared to 62% (95% CI, 48-76%) in patients receiving a 'high' CD34+ cell dose (>8.3 x 10(6)/kg) (P=0.01). At a median follow-up of 59 months, this has not translated into a difference in relapse. In patients evaluable for cGVHD, RFS was significantly higher in patients receiving a 'low' CD34+ cell dose as compared to those receiving a 'high' CD34+ cell dose (P=0.04). This difference was mainly because of a significantly higher cGVHD-associated mortality (P=0.01). Efforts to accelerate engraftment by increasing CD34+ cell dose must be counterbalanced with the risk of detrimental cGVHD.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0887-6924
|
| pubmed:author |
pubmed-author:AttarSS,
pubmed-author:BilgenOO,
pubmed-author:BlaiseDD,
pubmed-author:BordigoniPP,
pubmed-author:BourhisJ HJH,
pubmed-author:CahnJ YJY,
pubmed-author:FauchetAA,
pubmed-author:FegueuxNN,
pubmed-author:GuyotatDD,
pubmed-author:IfrahNN,
pubmed-author:JouetJ PJP,
pubmed-author:JourdanEE,
pubmed-author:KuentzMM,
pubmed-author:MaraninchiDD,
pubmed-author:MichalletMM,
pubmed-author:MilpiedNN,
pubmed-author:MohtyMM,
pubmed-author:ReiffersJJ,
pubmed-author:SadounAA,
pubmed-author:SuttonLL
|
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
869-75
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12750699-Acute Disease,
pubmed-meshheading:12750699-Adolescent,
pubmed-meshheading:12750699-Adult,
pubmed-meshheading:12750699-Antigens, CD34,
pubmed-meshheading:12750699-Female,
pubmed-meshheading:12750699-Graft vs Host Disease,
pubmed-meshheading:12750699-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:12750699-HLA Antigens,
pubmed-meshheading:12750699-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:12750699-Histocompatibility Testing,
pubmed-meshheading:12750699-Humans,
pubmed-meshheading:12750699-Infection,
pubmed-meshheading:12750699-Leukemia, Myeloid,
pubmed-meshheading:12750699-Male,
pubmed-meshheading:12750699-Middle Aged,
pubmed-meshheading:12750699-Myelodysplastic Syndromes,
pubmed-meshheading:12750699-Neoplasm Recurrence, Local,
pubmed-meshheading:12750699-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:12750699-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:12750699-Siblings,
pubmed-meshheading:12750699-Survival Rate,
pubmed-meshheading:12750699-Tissue Donors,
pubmed-meshheading:12750699-Transplantation, Isogeneic,
pubmed-meshheading:12750699-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
|
| pubmed:affiliation |
Institut Paoli-Calmettes, Marseille, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|